Nurix Therapeutics Management
Management criteria checks 3/4
Nurix Therapeutics' CEO is Arthur Sands, appointed in Sep 2014, has a tenure of 11.33 years. total yearly compensation is $5.81M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $5.39M. The average tenure of the management team and the board of directors is 5.5 years and 3.8 years respectively.
Key information
Arthur Sands
Chief executive officer
US$5.8m
Total compensation
| CEO salary percentage | 10.55% |
| CEO tenure | 11.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 5.5yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Nov 16
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Oct 12Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones
Oct 11Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price
Sep 30Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Aug 18Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Jul 14Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being
May 12Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential
Apr 17Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Apr 17Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Mar 22Nurix Therapeutics: A Story To Monitor
Feb 18Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth
Jan 30Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me
Jan 05Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%
Nov 07Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth
Oct 31Nurix: An Attractive Early-Stage Biotech Play
Oct 08Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares
Sep 07Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data
Sep 04Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans
Jul 15Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Jun 19What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You
May 29Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2025 | n/a | n/a | -US$245m |
| May 31 2025 | n/a | n/a | -US$207m |
| Feb 28 2025 | n/a | n/a | -US$208m |
| Nov 30 2024 | US$6m | US$613k | -US$194m |
| Aug 31 2024 | n/a | n/a | -US$177m |
| May 31 2024 | n/a | n/a | -US$165m |
| Feb 29 2024 | n/a | n/a | -US$145m |
| Nov 30 2023 | US$4m | US$591k | -US$144m |
| Aug 31 2023 | n/a | n/a | -US$149m |
| May 31 2023 | n/a | n/a | -US$157m |
| Feb 28 2023 | n/a | n/a | -US$179m |
| Nov 30 2022 | US$9m | US$572k | -US$180m |
| Aug 31 2022 | n/a | n/a | -US$171m |
| May 31 2022 | n/a | n/a | -US$154m |
| Feb 28 2022 | n/a | n/a | -US$135m |
| Nov 30 2021 | US$5m | US$539k | -US$117m |
| Aug 31 2021 | n/a | n/a | -US$99m |
| May 31 2021 | n/a | n/a | -US$89m |
| Feb 28 2021 | n/a | n/a | -US$63m |
| Nov 30 2020 | US$17m | US$521k | -US$43m |
| Aug 31 2020 | n/a | n/a | -US$37m |
| May 31 2020 | n/a | n/a | -US$21m |
| Feb 29 2020 | n/a | n/a | -US$24m |
| Nov 30 2019 | US$1m | US$474k | -US$22m |
Compensation vs Market: Arthur's total compensation ($USD5.81M) is about average for companies of similar size in the US market ($USD5.37M).
Compensation vs Earnings: Arthur's compensation has increased whilst the company is unprofitable.
CEO
Arthur Sands (63 yo)
Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.3yrs | US$5.81m | 0.30% $ 5.4m | |
| Chief Financial Officer | 9.8yrs | US$2.02m | 0.037% $ 657.4k | |
| Chief Scientific Officer | 5.6yrs | US$2.03m | 0.076% $ 1.3m | |
| Chief Legal Officer | 6.3yrs | US$2.02m | 0.050% $ 890.2k | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Senior Accounting Manager | no data | no data | no data | |
| Chief Technical Officer | 1.7yrs | no data | no data | |
| Chief Business Officer | 5.5yrs | no data | no data | |
| Senior VP & Head of Early Drug Discovery | 5yrs | no data | no data | |
| Senior Vice President of Information Technology | 4yrs | no data | no data | |
| VP & Head of Clinical Science | 4yrs | no data | no data |
Experienced Management: NRIX's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.3yrs | US$5.81m | 0.30% $ 5.4m | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 6.4yrs | US$371.62k | 0.011% $ 187.9k | |
| Member of Medical Advisory Board | 3yrs | no data | no data | |
| Independent Director | 4.3yrs | US$342.01k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 9.8yrs | US$355.76k | 0.033% $ 582.9k | |
| Independent Director | 4.3yrs | US$338.68k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$336.18k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Director | 1.3yrs | US$821.99k | 0% $ 0 |
Experienced Board: NRIX's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 09:44 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2024/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nurix Therapeutics, Inc. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| Zhiqiang Shu | Berenberg |